AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,700,630 | +131.5% | 386,565 | +139.1% | 0.01% | +100.0% |
| Q2 2023 | $2,030,889 | -35.5% | 161,695 | -43.0% | 0.00% | -25.0% |
| Q1 2023 | $3,147,131 | +83.1% | 283,781 | +101.5% | 0.00% | +33.3% |
| Q4 2022 | $1,719,253 | -100.0% | 140,807 | -60.0% | 0.00% | -50.0% |
| Q3 2022 | $3,672,228,000 | -0.5% | 351,746 | +2.4% | 0.01% | 0.0% |
| Q2 2022 | $3,690,822,000 | -30.6% | 343,652 | -38.8% | 0.01% | -14.3% |
| Q1 2022 | $5,318,106,000 | -27.1% | 561,574 | -11.0% | 0.01% | -30.0% |
| Q4 2021 | $7,291,804,000 | +30.3% | 631,325 | +7.7% | 0.01% | +25.0% |
| Q3 2021 | $5,596,806,000 | -23.1% | 586,053 | -22.4% | 0.01% | -20.0% |
| Q2 2021 | $7,278,595,000 | -5.5% | 755,041 | -3.1% | 0.01% | -9.1% |
| Q1 2021 | $7,699,711,000 | -41.5% | 779,323 | +36.6% | 0.01% | -54.2% |
| Q4 2020 | $13,169,266,000 | +146.2% | 570,345 | +50.5% | 0.02% | +200.0% |
| Q3 2020 | $5,349,249,000 | +1096.6% | 378,842 | +1177.9% | 0.01% | +700.0% |
| Q2 2020 | $447,047,000 | -65.5% | 29,645 | -78.9% | 0.00% | -66.7% |
| Q1 2020 | $1,295,365,000 | +249.9% | 140,191 | +268.8% | 0.00% | +200.0% |
| Q4 2019 | $370,256,000 | +1.8% | 38,014 | -16.2% | 0.00% | 0.0% |
| Q3 2019 | $363,835,000 | +11.3% | 45,366 | +73.2% | 0.00% | 0.0% |
| Q2 2019 | $326,814,000 | -45.7% | 26,187 | -40.8% | 0.00% | 0.0% |
| Q1 2019 | $601,487,000 | +1329.6% | 44,227 | +907.0% | 0.00% | – |
| Q4 2018 | $42,075,000 | -67.9% | 4,392 | -59.5% | 0.00% | – |
| Q3 2018 | $130,995,000 | -15.9% | 10,835 | +8.7% | 0.00% | – |
| Q2 2018 | $155,716,000 | -74.0% | 9,969 | -75.0% | 0.00% | -100.0% |
| Q1 2018 | $598,742,000 | +19.3% | 39,810 | +14.1% | 0.00% | 0.0% |
| Q4 2017 | $502,024,000 | +72.0% | 34,887 | +80.2% | 0.00% | 0.0% |
| Q3 2017 | $291,904,000 | -57.4% | 19,357 | -71.5% | 0.00% | -50.0% |
| Q2 2017 | $684,881,000 | +5227.7% | 68,012 | +3672.2% | 0.00% | – |
| Q1 2017 | $12,855,000 | -28.5% | 1,803 | -50.2% | 0.00% | – |
| Q4 2016 | $17,986,000 | -77.4% | 3,619 | -66.4% | 0.00% | – |
| Q3 2016 | $79,617,000 | +194.6% | 10,759 | +117.4% | 0.00% | – |
| Q2 2016 | $27,027,000 | -89.5% | 4,950 | -81.3% | 0.00% | -100.0% |
| Q4 2015 | $257,244,000 | -22.2% | 26,520 | +12.2% | 0.00% | 0.0% |
| Q3 2015 | $330,682,000 | +191.3% | 23,637 | +194.7% | 0.00% | – |
| Q2 2015 | $113,511,000 | +105985.0% | 8,022 | +24968.8% | 0.00% | – |
| Q2 2014 | $107,000 | +872.7% | 32 | +540.0% | 0.00% | – |
| Q1 2014 | $11,000 | -98.8% | 5 | -98.7% | 0.00% | – |
| Q4 2013 | $926,000 | -97.0% | 394 | -97.1% | 0.00% | – |
| Q2 2013 | $31,161,000 | – | 13,374 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |